ClinicalTrials.gg
Active, not recruitingNCT05144854Updated Jun 25, 2026

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

A Phase 3 interventional study of ONO-4538 and Ipilimumab in Gastric Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 57 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing nivolumab in Stomach Neoplasms — 6 open to participants now, 13 under way, 2 of them phase 3. Nivolumab · Stomach Neoplasms.

Enrollment
5th of 30
626 · median 49
Started
2021
with 1 other
Phase 3
6 of 30
1 open now
Primary completion
2025-10
later than 4 of 12 live
Registered
20th of 30
by date

Among the 30 studies testing nivolumab in Stomach Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 3, reaches primary completion later than 4 of the 12 other live ones, and was the 20th registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 30 studies testing nivolumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing nivolumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) that has been confirmed to be predominant adenocarcinoma
  2. (ECOG) Performance Status (PS) score 0 or 1
  3. Participants who have a of at least 3 months

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history or complications of multiple cancers
  2. Participants with a complication or history of severe to any other antibody products
  3. Participants with concurrent disease or a history of chronic or recurrent autoimmune disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
626 participants (actual)

Study arms

  • Experimental
    ONO-4538 + ipilimumab + chemotherapy

    Drug: ONO-4538 · Drug: Ipilimumab · Drug: Oxaliplatin · Drug: Capecitabine · Drug: S-1

  • Active comparator
    Chemotherapy

    Drug: Oxaliplatin · Drug: Capecitabine · Drug: S-1

Interventions

  • Specified dose on specified days

    Also known as: Nivolumab, Opdivo

  • Specified dose on specified days

    Also known as: BMS-734016, Yervoy

  • Specified dose on specified days

  • Specified dose on specified days

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    Specified dose on specified days

    Also known as: Tegafur-gimeracil-oteracil potassium

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    (N/A)

    Time frame: up to 3 years

Secondary outcomes

  1. Progression-free survival (PFS) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  2. Objective response rate (ORR) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  3. Best overall response (BOR) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  4. Duration of response (DOR) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  5. Disease control rate (DCR) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  6. Time to response (TTR) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  7. Maximum percent change in the sum diameters of the target lesions (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  8. Progression-free survival after the next line of therapy (PFS2) (site investigator assessment)

    (N/A)

    Time frame: up to 3 years

  9. Adverse event

    (N/A)

    Time frame: Up to 30 days after the last dose

07

Study locations

57 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Oct 2025, 47 months.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 47 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2021
First posted
Dec 3, 2021
StartActual
Nov 5, 2021
Primary completionActual
Oct 20, 2025
CompletionEst.
May 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05144854
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Nov 5, 2021
Primary completion
Oct 20, 2025
Completion
May 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion